Valeant agrees to buy Coria Labs
- Share via
From Times Wire Services
Valeant Pharmaceuticals International agreed to buy Coria Laboratories for $95 million, adding the closely held drug maker’s U.S. skin drugs.
Valeant will buy all outstanding shares of the Fort Worth company from Coria parent DFB Pharmaceuticals Inc. and other shareholders, Valeant said. The deal will add to Valeant’s earnings next year, the Aliso Viejo drug maker said.
Valeant’s products include Efudex for sun-damaged skin and Virazole for infant respiratory infections.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
